André F et al. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive human epidermal growth factor receptor-2–negative advanced breast cancer: Final overall survival results from SOLAR-1. Ann Oncol 2021;32(2):208-17.Abstract
Barcenas CH et al. Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: The CONTROL trial. Ann Oncol 2020;31(9):1223-30.Abstract
Bardia A et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med 2021;384(16):1529-41.Abstract
Chan A et al. Final efficacy results of neratinib in HER2-positive hormone receptor-positive early-stage breast cancer from the Phase III ExteNET trial. Clin Breast Cancer 2021;21(1):80-91.Abstract
Cortés J et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med 2022;386(12):1143-54.Abstract
Curigliano G et al. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): Final overall survival analysis. Ann Oncol 2022;33(3):321-29.Abstract
Gnant M et al. Adjuvant palbociclib in HR+/HER2- early breast cancer: Final results from 5,760 patients in the randomized phase III PALLAS trial. SABCS 2021;Abstract GS1-07
Harbeck N et al. Letter to the Editor for 'Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: Updated efficacy and Ki-67 analysis from the monarchE study'. Ann Oncol 2022 Feb;33(2):227-28.Abstract
Harbeck N et al. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: Updated efficacy and Ki-67 analysis from the monarchE study. Ann Oncol 2021 Dec;32(12):1571-81.Abstract
Hortobagyi GN et al. Overall survival results from the Phase III MONALEESA-2 trial of postmenopausal patients with HR+/HER2- advanced breast cancer treated with endocrine therapy +/- Ribociclib. ESMO 2021;Abstract LBA17_PR
Johnston SRD et al. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE). J Clin Oncol 2020;38(34):3987-98.Abstract
Rugo HS et al. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: Safety and patient-reported outcomes form the monarchE study. Ann Oncol 2022 Mar 23;S0923-7534(22)00383-0.Abstract
Rugo HS et al. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): One cohort of a phase 2, multicentre, open-label, non-comparative study. Lancet Oncol 2021;22(4): 489-98.Abstract
Rugo HS et al. Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with PIK3CA-mutated (mut) hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDKi) + aromatase inhibitor (AI): BYLieve study results. ASCO 2020;Abstract 1006
Schmid P et al. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. N Engl J Med 2022;386(6):556-67.Abstract
Schmid P et al. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med 2020;382:810-21.Abstract
Slamon DJ et al. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: Updated overall survival. Ann Oncol 2021 Aug;32(8):1015-24.Abstract
Tutt ANJ et al. Pre-specified event driven analysis of overall survival (OS) in the OLYMPIA phase III trial of adjuvant Olaparib (OL) in germline BRCA1/2 mutation (gBRCAm) associated with breast cancer. ESMO Virtual Plenary 2022;Abstract VP1-2022